High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2426-2432

  Lee, Young Joo ^a,b   Cho, Arthur ^b   Cho, Byoung Chul ^a,b   Yun, Mijin ^b   Kim, Se Kyu ^b   Chang, Joon ^b   Moon, Jin Wook ^b   Park, In Kyu ^b   Choi, Hye Jin ^a,b   Kim, Joo Hang ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; HAZARD RATIO; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; STANDARDIZED UPTAKE VALUE;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SMALL CELL LUNG CARCINOMA;

EID: 65249108701     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2258     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics; 2002. CA Cancer J Clin 2005;55:74-108.
2. Pass H, Mitchell J, Jonson D,Turrisi A, Minna J. Lung cancer, principals and practice. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000.
3. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973;4:31 -42.
4. Paesmans M, SculierJP, Lecomte J, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4con- secutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523-33.
5. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. The impact of additional prognostic factorson survival and their relationship with theanatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-66.
6. Jeremic B, Shibamoto Y, Nikolic N, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:2092-9.
7. Diniz G, Unlu I, Gokce T, et al. Evaluation of curative and palliative radiotherapy efficacy in extensive stage small cell lung cancer. Saudi Med J 2006;27:992-6.
8. Shepherd FA, Ginsberg RJ, Haddad R, et al. Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group. J Clin Oncol 1993;11:1592-7.
9. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE,WolfeWG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg1995;60:1348-52.
10. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res2000;6:3837-44.
11. 11.PillotG,Siegel BA,Govindan R. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol 2006;1:152-9.
12. max)measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
13. Ikenaga N, Otomo N,Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007;73: 1151 -7.
14. 18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys2004;59:1295-300.
15. van Westreenen HL, Plukker JT, Cobben DC, Verhoogt CJ, Groen H, Jager PL. Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 2005;185:436-40.
16. Vesselle H, Freeman JD,Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13: 3255-63.
17. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small- cell lung carcinoma. J Clin Oncol 2008;26:1459-64.
18. BradleyJD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. JClin Oncol 2004;22:3248-54.
19. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F] FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003;30:78-84.
20. 18Fluoro- deoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl CancerInst2007;99:1753-67.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl CancerInst2000;92:205-16.
22. Shepherd FA,Crowley J,Van Houtte P,et al.The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forth- coming (seventh) edition of the tumor,node,metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-77.
23. Oøsterlind K. LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A commentary. Lung Cancer 2000;30:51 -3.
24. Cohen MH,Makuch R,Johnston-EarlyA,etal.Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981;65:187-95.
25. Han JY, Cho KH, Lee DH, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 2005;23: 3488-94.
26. Saito H,TakadaY, IchinoseY, et al. PhaseII studyof etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 2006;24:5247-52.
27. Kubota K, Nishiwaki Y, SugiuraT, et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 2005;11:5534-8.
28. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo- controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002;20:4434-9.
29. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25: 4278-84.
30. Dowlati A,Subbiah S,CooneyM,etal. PhaseII trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer2007;56:377-81.
31. LeeSM, JamesL,Buchler T, Snee M, Ellis P, Hackshaw A. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 2008;59:364-8.
32. Lee KH, Lee SH, Kim DW, et al. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006;12:4232-6.
33. 18F-fluoro-2-deoxyglucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. Clin Cancer Res 2008;14:2036-41.